Insider Trades75 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Sell | CRNX | Richard Scott Struthers | President & CEO | 1,937,600 | $35.55 | $8.9B | -0.32% | +224.16% | $68.9M | +0.00% | — | Buy Now |
| Apr 8, 2026 | Sell | CRNX | Jeff E. Knight | Chief Dev. & Operating Officer | 163,597 | $31.63 | $8.9B | -0.32% | +224.16% | $5.2M | -0.87% | 10b5-1 | Buy Now |
| Mar 16, 2026 | Sell | CRNX | Jeff E. Knight | Chief Operating Officer | 9,911 | $37.37 | $8.9B | -0.32% | +224.16% | $370.4K | -4.17% | 10b5-1 | Buy Now |
| Mar 16, 2026 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 10,612 | $37.37 | $8.9B | -0.32% | +224.16% | $396.6K | -3.67% | 10b5-1 | Buy Now |
| Mar 16, 2026 | Sell | CRNX | Richard Scott Struthers | President & CEO | 21,981 | $37.37 | $8.9B | -0.32% | +224.16% | $821.5K | -2.62% | 10b5-1 | Buy Now |
| Mar 3, 2026 | Sell | CRNX | Tobin Schilke | Chief Financial Officer | 6,713 | $39.67 | $8.9B | -0.32% | +224.16% | $266.3K | -7.91% | 10b5-1 | Buy Now |
| Jan 5, 2026 | Sell | CRNX | Isabel Kalofonos | Chief Commercial Officer | 5,000 | $47.80 | $8.9B | -0.32% | +224.16% | $239.0K | +0.00% | 10b5-1 | Buy Now |
| Dec 26, 2025 | Buy | CRNX | Stephen F. Betz | Chief Scientific Officer | 18,000 | $1.91 | $8.9B | -0.32% | +224.16% | $34.4K | +9.46% | — | Buy Now |
| Dec 18, 2025 | Buy | CRNX | Richard Scott Struthers | President & CEO | 44,742 | $13.09 | $8.9B | -0.32% | +224.16% | $585.9K | +4.89% | — | Buy Now |
| Dec 1, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 10,000 | $30.95 | $8.9B | -0.32% | +224.16% | $309.6K | +0.00% | 10b5-1 | Buy Now |
| Nov 3, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 10,000 | $29.78 | $8.9B | -0.32% | +224.16% | $297.8K | +0.00% | 10b5-1 | Buy Now |
| Oct 1, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 10,000 | $29.35 | $8.9B | -0.32% | +224.16% | $293.5K | +0.00% | 10b5-1 | Buy Now |
| Sep 26, 2025 | Sell | CRNX | Richard Scott Struthers | President & CEO | 4,000 | $45.00 | $8.9B | -0.32% | +224.16% | $180.0K | -3.64% | 10b5-1 | Buy Now |
| Sep 2, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 10,000 | $24.50 | $8.9B | -0.32% | +224.16% | $244.9K | +0.00% | 10b5-1 | Buy Now |
| Aug 22, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 60,000 | $23.66 | $8.9B | -0.32% | +224.16% | $1.4M | +0.00% | 10b5-1 | Buy Now |
| Aug 20, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 6,492 | $29.18 | $8.9B | -0.32% | +224.16% | $189.4K | -8.92% | 10b5-1 | Buy Now |
| Jun 12, 2025 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 185,653 | $18.49 | $8.9B | -0.32% | +224.16% | $3.4M | -1.43% | 10b5-1 | Buy Now |
| May 14, 2025 | Sell | CRNX | Richard Scott Struthers | President & CEO | 180,800 | $31.29 | $8.9B | -0.32% | +224.16% | $5.7M | +0.00% | — | Buy Now |
| Apr 2, 2025 | Buy | CRNX | Richard Scott Struthers | President & CEO | 81,270 | $1.91 | $8.9B | -0.32% | +224.16% | $155.2K | +24.69% | — | Buy Now |
| Mar 19, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 2,515 | $34.20 | $8.9B | -0.32% | +224.16% | $86.0K | -1.71% | 10b5-1 | Buy Now |
| Mar 19, 2025 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 5,770 | $34.20 | $8.9B | -0.32% | +224.16% | $197.4K | -2.58% | 10b5-1 | Buy Now |
| Mar 19, 2025 | Sell | CRNX | Jeff E. Knight | Chief Operating Officer | 7,162 | $34.20 | $8.9B | -0.32% | +224.16% | $245.0K | -3.92% | 10b5-1 | Buy Now |
| Mar 19, 2025 | Sell | CRNX | Richard Scott Struthers | President & CEO | 17,338 | $34.20 | $8.9B | -0.32% | +224.16% | $593.0K | -2.56% | 10b5-1 | Buy Now |
| Feb 3, 2025 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 10,000 | $27.98 | $8.9B | -0.32% | +224.16% | $279.8K | +0.00% | 10b5-1 | Buy Now |
| Jan 3, 2025 | Buy | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 32,500 | $33.35 | $8.9B | -0.32% | +224.16% | $1.1M | +1.02% | 10b5-1 | Buy Now |
| Dec 16, 2024 | Buy | CRNX | Stephen F. Betz | Chief Scientific Officer | 2,331 | $1.91 | $8.9B | -0.32% | +224.16% | $4.5K | +0.94% | — | Buy Now |
| Dec 2, 2024 | Sell | CRNX | Richard Scott Struthers | President & CEO | 10,000 | $57.57 | $8.9B | -0.32% | +224.16% | $575.7K | -9.09% | 10b5-1 | Buy Now |
| Nov 22, 2024 | Sell | CRNX | Jeff E. Knight | Chief Operating Officer | 501 | $56.52 | $8.9B | -0.32% | +224.16% | $28.3K | -0.96% | 10b5-1 | Buy Now |
| Oct 3, 2024 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 28,750 | $35.76 | $8.9B | -0.32% | +224.16% | $1.0M | +0.00% | 10b5-1 | Buy Now |
| Sep 26, 2024 | Sell | CRNX | Marc Wilson | CFO | 50,000 | $33.20 | $8.9B | -0.32% | +224.16% | $1.7M | +0.00% | 10b5-1 | Buy Now |
| Sep 10, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 1,035 | $51.50 | $8.9B | -0.32% | +224.16% | $53.3K | -1.49% | 10b5-1 | Buy Now |
| Aug 26, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $53.19 | $8.9B | -0.32% | +224.16% | $159.6K | -4.13% | 10b5-1 | Buy Now |
| Aug 12, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $47.68 | $8.9B | -0.32% | +224.16% | $143.0K | -3.97% | 10b5-1 | Buy Now |
| Jul 25, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $53.43 | $8.9B | -0.32% | +224.16% | $160.3K | -3.82% | 10b5-1 | Buy Now |
| Jul 25, 2024 | Sell | CRNX | Marc Wilson | CFO | 38,112 | $31.58 | $8.9B | -0.32% | +224.16% | $1.2M | +0.00% | 10b5-1 | Buy Now |
| Jul 15, 2024 | Sell | CRNX | Marc Wilson | CFO | 50,000 | $37.51 | $8.9B | -0.32% | +224.16% | $1.9M | +0.00% | 10b5-1 | Buy Now |
| Jul 15, 2024 | Sell | CRNX | Jeff E. Knight | Chief Operating Officer | 53,073 | $39.08 | $8.9B | -0.32% | +224.16% | $2.1M | -0.19% | 10b5-1 | Buy Now |
| Jul 10, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $48.55 | $8.9B | -0.32% | +224.16% | $145.7K | -3.68% | 10b5-1 | Buy Now |
| Jul 5, 2024 | Sell | CRNX | James Hassard | Chief Commercial Officer | 30,000 | $31.91 | $8.9B | -0.32% | +224.16% | $957.1K | +0.00% | 10b5-1 | Buy Now |
| Jul 3, 2024 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 28,750 | $30.88 | $8.9B | -0.32% | +224.16% | $887.8K | +0.00% | 10b5-1 | Buy Now |
| Jun 28, 2024 | Sell | CRNX | Marc Wilson | CFO | 64,258 | $26.45 | $8.9B | -0.32% | +224.16% | $1.7M | +0.00% | 10b5-1 | Buy Now |
| Jun 26, 2024 | Sell | CRNX | Jeff E. Knight | Chief Operating Officer | 956 | $44.38 | $8.9B | -0.32% | +224.16% | $42.4K | -1.79% | 10b5-1 | Buy Now |
| Jun 25, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $45.37 | $8.9B | -0.32% | +224.16% | $136.1K | -3.59% | 10b5-1 | Buy Now |
| Jun 24, 2024 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 19,000 | $31.31 | $8.9B | -0.32% | +224.16% | $594.9K | +0.00% | — | Buy Now |
| Jun 21, 2024 | Sell | CRNX | James Hassard | Chief Commercial Officer | 30,000 | $32.20 | $8.9B | -0.32% | +224.16% | $965.9K | +0.00% | 10b5-1 | Buy Now |
| Jun 10, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $43.86 | $8.9B | -0.32% | +224.16% | $131.6K | -3.46% | 10b5-1 | Buy Now |
| May 28, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $47.49 | $8.9B | -0.32% | +224.16% | $142.5K | -3.35% | 10b5-1 | Buy Now |
| May 10, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $49.43 | $8.9B | -0.32% | +224.16% | $148.3K | -3.24% | 10b5-1 | Buy Now |
| May 8, 2024 | Sell | CRNX | Richard Scott Struthers | President & CEO | 214,896 | $29.34 | $8.9B | -0.32% | +224.16% | $6.3M | +0.00% | 10b5-1 | Buy Now |
| Apr 18, 2024 | Sell | CRNX | Richard Scott Struthers | President & CEO | 350 | $43.01 | $8.9B | -0.32% | +224.16% | $15.1K | -0.14% | — | Buy Now |
| Apr 15, 2024 | Buy | CRNX | Richard Scott Struthers | President & CEO | 20,000 | $1.91 | $8.9B | -0.32% | +224.16% | $38.2K | +6.27% | — | Buy Now |
| Apr 15, 2024 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 28,750 | $30.68 | $8.9B | -0.32% | +224.16% | $882.0K | +0.00% | 10b5-1 | Buy Now |
| Apr 4, 2024 | Sell | CRNX | Richard Scott Struthers | President & CEO | 81,902 | $29.23 | $8.9B | -0.32% | +224.16% | $2.4M | +0.00% | 10b5-1 | Buy Now |
| Mar 22, 2024 | Sell | CRNX | Jeff E. Knight | Chief Operating Officer | 62,359 | $34.53 | $8.9B | -0.32% | +224.16% | $2.2M | -0.73% | — | Buy Now |
| Mar 20, 2024 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 29,464 | $30.80 | $8.9B | -0.32% | +224.16% | $907.6K | -0.13% | — | Buy Now |
| Mar 18, 2024 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 411 | $38.14 | $8.9B | -0.32% | +224.16% | $15.7K | -1.42% | 10b5-1 | Buy Now |
| Mar 18, 2024 | Sell | CRNX | James Hassard | Chief Commercial Officer | 1,741 | $38.14 | $8.9B | -0.32% | +224.16% | $66.4K | -5.62% | 10b5-1 | Buy Now |
| Mar 18, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,655 | $38.14 | $8.9B | -0.32% | +224.16% | $139.4K | -3.80% | 10b5-1 | Buy Now |
| Mar 18, 2024 | Sell | CRNX | Jeff E. Knight | Chief Operating Officer | 4,283 | $38.14 | $8.9B | -0.32% | +224.16% | $163.4K | -7.23% | 10b5-1 | Buy Now |
| Mar 18, 2024 | Sell | CRNX | Marc Wilson | CFO | 10,925 | $41.17 | $8.9B | -0.32% | +224.16% | $449.8K | -4.57% | 10b5-1 | Buy Now |
| Mar 18, 2024 | Sell | CRNX | Richard Scott Struthers | President & CEO | 12,687 | $38.14 | $8.9B | -0.32% | +224.16% | $483.9K | -5.06% | 10b5-1 | Buy Now |
| Feb 12, 2024 | Sell | CRNX | Richard Scott Struthers | President & CEO | 120,000 | $39.30 | $8.9B | -0.32% | +224.16% | $4.7M | +0.00% | — | Buy Now |
| Jan 25, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $37.26 | $8.9B | -0.32% | +224.16% | $111.8K | -3.93% | 10b5-1 | Buy Now |
| Jan 10, 2024 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $37.65 | $8.9B | -0.32% | +224.16% | $113.0K | -3.78% | 10b5-1 | Buy Now |
| Jan 3, 2024 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 28,750 | $25.95 | $8.9B | -0.32% | +224.16% | $745.9K | +0.00% | 10b5-1 | Buy Now |
| Jan 2, 2024 | Sell | CRNX | Marc Wilson | CFO | 20,000 | $22.38 | $8.9B | -0.32% | +224.16% | $447.5K | +0.00% | 10b5-1 | Buy Now |
| Dec 26, 2023 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $35.89 | $8.9B | -0.32% | +224.16% | $107.7K | -3.65% | 10b5-1 | Buy Now |
| Dec 21, 2023 | Sell | CRNX | Dana Pizzuti | Chief Med and Dev Officer | 19,166 | $25.73 | $8.9B | -0.32% | +224.16% | $493.1K | +0.00% | — | Buy Now |
| Dec 11, 2023 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $32.87 | $8.9B | -0.32% | +224.16% | $98.6K | -3.52% | 10b5-1 | Buy Now |
| Nov 27, 2023 | Sell | CRNX | Stephen F. Betz | Chief Scientific Officer | 3,000 | $31.84 | $8.9B | -0.32% | +224.16% | $95.5K | -3.40% | 10b5-1 | Buy Now |
| Nov 9, 2023 | Buy | CRNX | Richard Scott Struthers | President & CEO | 50,000 | $1.91 | $8.9B | -0.32% | +224.16% | $95.5K | +21.12% | — | Buy Now |
| Nov 2, 2023 | Sell | CRNX | Richard Scott Struthers | President & CEO | 400,000 | $19.92 | $8.9B | -0.32% | +224.16% | $8.0M | +0.00% | — | Buy Now |
| Nov 1, 2023 | Sell | CRNX | Marc Wilson | CFO | 20,000 | $19.02 | $8.9B | -0.32% | +224.16% | $380.3K | +0.00% | — | Buy Now |
| Oct 17, 2023 | Sell | CRNX | Alan Seth Krasner | Chief Medical Officer | 14,000 | $21.00 | $8.9B | -0.32% | +224.16% | $294.1K | +0.00% | — | Buy Now |
| Aug 14, 2023 | Buy | CRNX | Richard Scott Struthers | President & CEO | 10,000 | $1.91 | $8.9B | -0.32% | +224.16% | $19.1K | +3.61% | — | Buy Now |